Avalo Therapeutics AVTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$84.74M-8.3% | -$78.26M+21.6% | -$99.88M-116% | -$46.22M-163% | $73.01M+308% | ||
| $226K-34.3% | $344K-13.1% | $396K+6.7% | $371K+37.4% | $270K+59.8% | ||
| $13.96M+2.5% | $13.62M+13.3% | $12.02M+12.2% | $10.71M+26.5% | $8.46M+44.6% | ||
| $169K+2.4% | $165K+11.5% | $148K+19.4% | $124K+7.8% | $115K+0.9% | ||
| -$325K-123% | -$146K+89.1% | -$1.34M-178% | $1.71M+829% | -$235K-44.2% | ||
| $6.87M+3.1% | $6.66M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$59.69M-16.0% | -$51.46M+1.5% | -$52.26M-10.2% | -$47.42M+9.4% | -$52.31M-6.6% | ||
| —— | —— | —— | —— | —— | ||
| -$58.62M+30.3% | -$84.12M— | —— | —— | —— | ||
| $16.94M+14.8% | $14.76M+36,805% | $40K0.0% | $40K— | —— | ||
| $1.29M+153% | $510K0.0% | $510K+0.2% | $509K— | —— | ||
| $15.99M+9.6% | $14.59M-82.1% | $81.61M— | —— | —— | ||
| -$99.92M+15.7% | -$118.59M-117% | -$54.77M— | —— | —— | ||
| $796K+15.4% | $690K+40.0% | $493K— | —— | —— | ||
| -$8.66M+1.1% | -$8.76M-240% | $6.25M+221% | -$5.18M-94.0% | -$2.67M+15.8% | ||
| —— | $0-100% | $77.25K-50.0% | $154.5K-33.3% | $231.75K-25.0% | ||
| -$125K-43.7% | -$87K-181% | -$31K— | —— | —— | ||
| $6.87M+3.1% | $6.66M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $433.5K-50.0% | $867K-33.3% | $1.3M-25.0% | ||
| —— | $462K+33.3% | $346.5K+50.0% | $231K+100% | $115.5K— | ||
| —— | $0-100% | $17.34M-50.0% | $34.69M-33.3% | $52.03M-25.0% | ||
| $509K— | $0— | —— | —— | —— | ||
| —— | $0-100% | $78K-50.0% | $156K-33.3% | $234K-25.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Avalo Therapeutics generate?
- Avalo Therapeutics (AVTX) generated -$59.7M in operating cash flow over the trailing twelve months.
- Where does Avalo Therapeutics's cash flow data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
